Table of Contents Table of Contents
Previous Page  6 / 14 Next Page
Information
Show Menu
Previous Page 6 / 14 Next Page
Page Background

Note:

Page 17

April 15-16, 2019 | Milan, Italy

&

PUBLIC HEALTH,

EPIDEMIOLOGY AND NUTRITION

2

nd

World Congress on

CELL AND GENE THERAPY

2

nd

International Conference on

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

alliedacademies.com

YEARS

Joint Event on

Cell and Gene Therapy 2019 & Public Health Congress 2019

Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3

TECHNOLOGY TRENDS IN THE

DEVELOPMENT AND COMMERCIAL-

SCALE MANUFACTURING OF CELL AND

GENE THERAPIES

T

he cell and gene therapy industry has now exceeded 1000 clinical

trials and annual global financing increased 40% YOY to over $10B

(ARM 2018 Q3 Report). As the industry continues its monumental ex-

pansion, developers much find newmethods to scale their supply chains

to control costs, speed and reproducibility. Meanwhile new regulations

and standards are increasing pressure for more controlled processes, val-

idation and risk mitigation. Raw material documentation, supply chain

redundancy and closed manufacturing systems are key aspects to en-

abling the next wave of therapies. This talk will showcase some of the

latest trends in the industry, emerging technologies and best practices

that start early in development to enable robust, sustainable operations

and commercial success.

Bryan Poltilove, Arch Gen Intern Med 2019, Volume 3

DOI: 10.4066/2591-7951-C2-025

Bryan Poltilove is general manager of cell and

gene therapy, he has overall P&L responsibility

for the Thermo Fisher business segment, includ-

ing long-range product line strategy, investment

and day-to-day business operations. Previously,

he led a $350M business segment of cell biolo-

gy reagents and instrumentation. Prior to joining

Thermo Fisher, he served as the Director of Rev-

enue Strategy and Operations for the Corporate

Executive Board and held several roles with John-

son & Johnson. He holds Bachelor degrees in

Chemical Engineering and Economics from MIT

and an MBA from Northwestern University, USA.

bryan.poltilove@thermofisher.com

Bryan Poltilove

Thermo Fisher Scientific, USA

BIOGRAPHY